Diagnosis of elderly patients with heart failure

  • Luis Manzano
    Heart Failure and Vascular Risk Unit, Internal Medicine Department Hospital Universitario Ramón y Cajal, Universidad de Alcalá Madrid Spain
  • Carlos Escobar
    Cardiology Department Hospital Universitario La Paz Madrid Spain
  • John G.F. Cleland
    Department of Cardiology Castle Hill Hospital, Hull York Medical School, University of Hull Kingston upon Hull HU16 5JQ UK
  • Marcus Flather
    Department of Medicine University of East Anglia, Norwich Research Park Norwich NR4 7TJ UK

説明

<jats:p>The prevalence and mortality of heart failure (HF) increase with age. As a result, the early diagnosis of HF in this population is useful to reduce cardiovascular morbidity and probably mortality. However, the diagnosis of HF in the elderly is a challenge. These challenges arise from the under‐representation of elderly patients in diagnostic studies and clinical trials, the increasing prevalence of HF with relatively normal ejection fraction, the difficulty in accurate diagnosis, the underuse of diagnostic tests, and the presence of co‐morbidities. Particularly in the elderly, symptoms and signs of HF may be atypical and can be simulated or disguised by co‐morbidities such as respiratory disease, obesity, and venous insufficiency. This review aims to provide a practical clinical approach for the diagnosis of older patients with HF based on the scarce available evidence and our clinical experience. Therefore, it should be interpreted in many aspects as an opinion paper with practical implications. The most useful clinical symptoms are orthopnoea and paroxysmal nocturnal dyspnoea. However, confirmation of the diagnosis always requires further tests. Although natriuretic peptides accurately exclude cardiac dysfunction as a cause of symptoms, the optimal cut‐off level for ruling out HF in elderly patients with other co‐morbidities is still not clear. In our opinion, echocardiography should be performed in all elderly patients to confirm the diagnosis of HF, except in those cases with low clinical probability and a concentration of brain natriuretic peptide (BNP) or N‐terminal proBNP (NT‐proBNP) lower than 100 or 400 pg/mL, respectively.</jats:p>

収録刊行物

被引用文献 (2)*注記

もっと見る

問題の指摘

ページトップへ